Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
The Associated Press on MSN5d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...
Business Insider13h
Intra-Cellular Announces Positive Data For Caplyta As Maintenance Treatment For Schizophrenia
The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to relapse ...
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...
GlobalData on MSN1d
Teva’s long-lasting schizophrenia injectable shines in Phase III
Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...
THE WEEK1mon
The 'game-changing' treatment for schizophrenia
About one in 300 people worldwide are affected by schizophrenia, but for decades treatment options have been both static and limited. If the FDA approves the twice-daily pill on Thursday ...